235 related articles for article (PubMed ID: 7656393)
1. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
Yue K; Bian M; Zhu D; Liu W; Siu S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
3. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of serum lipid-bound sialic acid and carcinoembryonic antigen in patients with lung cancer].
Zhu X
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Feb; 13(1):25-7, 61. PubMed ID: 2165867
[TBL] [Abstract][Full Text] [Related]
5. [Serum lipid-bound sialic acid as a marker in lung cancer patients].
Iwahashi N
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Dec; 28(12):1599-607. PubMed ID: 2077205
[TBL] [Abstract][Full Text] [Related]
6. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
8. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy.
Stringou E; Chondros K; Kouvaris J; Kakari S; Papavassiliou K
Anticancer Res; 1992; 12(1):251-5. PubMed ID: 1567173
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum sialic acid, heat stable alkaline phosphatase and fucose as markers of breast carcinoma.
Patel PS; Baxi BR; Adhvaryu SG; Balar DB
Anticancer Res; 1990; 10(4):1071-4. PubMed ID: 2382978
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
11. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
12. [Application of multi-tumor markers in ovarian carcinoma].
Feng J; Qian H; Tian Y
Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
[TBL] [Abstract][Full Text] [Related]
13. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
[TBL] [Abstract][Full Text] [Related]
14. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
15. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
16. The significance of neopterin determination as a tumour marker in ovarian cancer.
Szarka G; Pulay T; Csömör S; Tran-Phoung-Mai ; Schumann B
Acta Chir Hung; 1988; 29(4):359-64. PubMed ID: 3239335
[TBL] [Abstract][Full Text] [Related]
17. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
[TBL] [Abstract][Full Text] [Related]
18. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
19. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
20. Importance of serum sialic acid and lactate dehydrogenase in diagnosis and treatment monitoring of cervical cancer patients.
Patel PS; Rawal GN; Balar DB
Gynecol Oncol; 1993 Sep; 50(3):294-9. PubMed ID: 8406190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
